AsianScientist (Aug. 29, 2011) – Takeda Pharmaceutical Company Limited announced today that it has initiated Phase II clinical trials of TAK-385 in Japan for the treatment of endometriosis and uterine fibroids.
TAK-385 is a luteinizing hormone-releasing hormone (LH-RH) receptor antagonist administered orally.
By preventing LH-RH from binding with the LH-RH receptor in the anterior pituitary gland and suppressing the secretion of luteinizing hormone (LH) and follicle stimulation hormone (FSH) from the anterior pituitary gland, TAK-385 controls the effect of LH and FSH on the ovary.
The overall effect is that TAK-385 reduces the level of estrogen in blood, which is known to be associated with the development of endometriosis and uterine fibroids, and is expected to improve the symptoms of these disorders.
The safety and efficacy of TAK-385 in subjects with endometriosis and uterine fibroids will be evaluated in two individual Phase II, double-blind, comparative studies, said the company’s press report.
According to Takeda, there are medical needs which cannot be met by the current therapies in the treatment of endometriosis and uterine fibroids, and the oral LH-RH antagonist TAK-385 could become a new treatment option for patients with these conditions.
——
Source: Takeda Pharmaceutical Co. Ltd.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
